AGWCA
VRTX icon

Annis Gardner Whiting Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Annis Gardner Whiting Capital Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$970K Buy
1,953
+28
+1% +$12.4K 0.15% 129
2026
Q1 		$860K Sell
1,925
-39
-2% -$18.2K 0.14% 130
2025
Q4 		$890K Sell
1,964
-3
-0.2% -$1.29K 0.17% 110
2025
Q3 		$770K Buy
1,967
+6
+0.3% +$2.51K 0.16% 111
2025
Q2 		$873K Buy
1,961
+22
+1% +$10.1K 0.3% 73
2025
Q1 		$940K Sell
1,939
-5
-0.3% -$2.33K 0.4% 56
2024
Q4 		$783K Hold
1,944
– – 0.22% 84
2024
Q3 		$904K Sell
1,944
-61
-3% -$29.3K 0.25% 75
2024
Q2 		$940K Buy
2,005
+1,809
+923% +$785K 0.27% 70
2024
Q1 		$81.9K Buy
196
+40
+26% +$16.9K 0.03% 311
2023
Q4 		$63.5K Hold
156
– – 0.03% 273
2023
Q3 		$54.2K Buy
+156
New +$54.6K 0.03% 275

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Annis Gardner Whiting Capital Advisors's VRTX Position: Q2 2026 in Review

Annis Gardner Whiting Capital Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 1.5% in Q2 2026, buying an estimated $12.4K and bringing the position to 1,953 shares worth $970K. The position accounts for 0.15% of the portfolio, ranked #129.

Annis Gardner Whiting Capital Advisors first reported a position in VRTX in Q3 2023 and has held it in 12 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Annis Gardner Whiting Capital Advisors held 1,953 shares of Vertex Pharmaceuticals worth $970K as of Q2 2026.
  • Annis Gardner Whiting Capital Advisors bought 28 Vertex Pharmaceuticals shares in Q2 2026, an estimated $12.4K.
  • Vertex Pharmaceuticals made up 0.15% of Annis Gardner Whiting Capital Advisors's portfolio in Q2 2026, its #129 holding.
  • Annis Gardner Whiting Capital Advisors first reported a position in Vertex Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.